Biological Treatment Evaluation in Thermoradiotherapy: Application in Cervical Cancer Patients

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2024 Jan 4

PMID 38177701

Authors

H P Kok

T D Herrera

J Crezee

Affiliations

Soon will be listed here.

Abstract

Background: Hyperthermia treatment quality is usually evaluated by thermal (dose) parameters, though hyperthermic radiosensitization effects are also influenced by the time interval between the two modalities. This work applies biological modelling for clinical treatment evaluation of cervical cancer patients treated with radiotherapy plus hyperthermia by calculating the equivalent radiation dose (EQD, i.e., the dose needed for the same effect with radiation alone). Subsequent analyses evaluate the impact of logistics.

Methods: Biological treatment evaluation was performed for 58 patients treated with 23-28 fractions of 1.8-2 Gy plus 4-5 weekly hyperthermia sessions. Measured temperatures (T50) and recorded time intervals between the radiotherapy and hyperthermia sessions were used to calculate the EQD using an extended linear quadratic (LQ) model with hyperthermic LQ parameters based on extensive experimental data. Next, the impact of a 30-min time interval (optimized logistics) as well as a 4‑h time interval (suboptimal logistics) was evaluated.

Results: Median average measured T50 and recorded time intervals were 41.2 °C (range 39.7-42.5 °C) and 79 min (range 34-125 min), respectively, resulting in a median total dose enhancement (D50) of 5.5 Gy (interquartile range [IQR] 4.0-6.6 Gy). For 30-min time intervals, the enhancement would increase by ~30% to 7.1 Gy (IQR 5.5-8.1 Gy; p < 0.001). In case of 4‑h time intervals, an ~ 40% decrease in dose enhancement could be expected: 3.2 Gy (IQR 2.3-3.8 Gy; p < 0.001). Normal tissue enhancement was negligible (< 0.3 Gy), even for short time intervals.

Conclusion: Biological treatment evaluation is a useful addition to standard thermal (dose) evaluation of hyperthermia treatments. Optimizing logistics to shorten time intervals seems worthwhile to improve treatment efficacy.

References

Stavrev P, Stavreva N, Ruggieri R, Nahum A, Tsonev P, Penev D . Theoretical investigation of the impact of different timing schemes in hypofractionated radiotherapy. Med Phys. 2021; 48(7):4085-4098. DOI: 10.1002/mp.14908. View

Notter M, Piazena H, Vaupel P . Hypofractionated re-irradiation of large-sized recurrent breast cancer with thermography-controlled, contact-free water-filtered infra-red-A hyperthermia: a retrospective study of 73 patients. Int J Hyperthermia. 2016; 33(2):227-236. DOI: 10.1080/02656736.2016.1235731. View

Bruggmoser G, Bauchowitz S, Canters R, Crezee H, Ehmann M, Gellermann J . Guideline for the clinical application, documentation and analysis of clinical studies for regional deep hyperthermia: quality management in regional deep hyperthermia. Strahlenther Onkol. 2012; 188 Suppl 2:198-211. DOI: 10.1007/s00066-012-0176-2. View

Krawczyk P, Eppink B, Essers J, Stap J, Rodermond H, Odijk H . Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci U S A. 2011; 108(24):9851-6. PMC: 3116433. DOI: 10.1073/pnas.1101053108. View

Jones E, Prosnitz L, Dewhirst M, Marcom P, Hardenbergh P, Marks L . Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clin Cancer Res. 2004; 10(13):4287-93. DOI: 10.1158/1078-0432.CCR-04-0133. View

Plataniotis G, Dale R . Use of concept of chemotherapy-equivalent biologically effective dose to provide quantitative evaluation of contribution of chemotherapy to local tumor control in chemoradiotherapy cervical cancer trials. Int J Radiat Oncol Biol Phys. 2008; 72(5):1538-43. DOI: 10.1016/j.ijrobp.2008.06.1911. View

Dewhirst M, Oleson J, Kirkpatrick J, Secomb T . Accurate Three-Dimensional Thermal Dosimetry and Assessment of Physiologic Response Are Essential for Optimizing Thermoradiotherapy. Cancers (Basel). 2022; 14(7). PMC: 8997141. DOI: 10.3390/cancers14071701. View

Canters R, Franckena M, van der Zee J, van Rhoon G . Complaint-adaptive power density optimization as a tool for HTP-guided steering in deep hyperthermia treatment of pelvic tumors. Phys Med Biol. 2008; 53(23):6799-820. DOI: 10.1088/0031-9155/53/23/010. View

Overgaard J . Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its surrounding normal tissue in vivo. Int J Radiat Oncol Biol Phys. 1980; 6(11):1507-17. DOI: 10.1016/0360-3016(80)90008-5. View

10.

van Rhoon G . Is CEM43 still a relevant thermal dose parameter for hyperthermia treatment monitoring?. Int J Hyperthermia. 2016; 32(1):50-62. DOI: 10.3109/02656736.2015.1114153. View

11.

Kok H, van Dijk I, Crama K, Franken N, Rasch C, Merks J . Re‑irradiation plus hyperthermia for recurrent pediatric sarcoma; a simulation study to investigate feasibility. Int J Oncol. 2018; 54(1):209-218. DOI: 10.3892/ijo.2018.4622. View

12.

van der Zee J, Gonzalez Gonzalez D, van Rhoon G, van Dijk J, van Putten W, Hart A . Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet. 2000; 355(9210):1119-25. DOI: 10.1016/s0140-6736(00)02059-6. View

13.

Kok H, Crezee J, Franken N, Stalpers L, Barendsen G, Bel A . Quantifying the combined effect of radiation therapy and hyperthermia in terms of equivalent dose distributions. Int J Radiat Oncol Biol Phys. 2014; 88(3):739-45. DOI: 10.1016/j.ijrobp.2013.11.212. View

14.

. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008; 26(35):5802-12. PMC: 2645100. DOI: 10.1200/JCO.2008.16.4368. View

15.

Myerson R, Roti J, Moros E, Straube W, Xu M . Modelling heat-induced radiosensitization: clinical implications. Int J Hyperthermia. 2004; 20(2):201-12. DOI: 10.1080/02656730310001609353. View

16.

Overgaard J, Nielsen O . The importance of thermotolerance for the clinical treatment with hyperthermia. Radiother Oncol. 1983; 1(2):167-78. DOI: 10.1016/s0167-8140(83)80019-x. View

17.

van Leeuwen C, Crezee J, Oei A, Franken N, Stalpers L, Bel A . The effect of time interval between radiotherapy and hyperthermia on planned equivalent radiation dose. Int J Hyperthermia. 2018; 34(7):901-909. DOI: 10.1080/02656736.2018.1468930. View

18.

STOLL A, GREENE L . Relationship between pain and tissue damage due to thermal radiation. J Appl Physiol. 1959; 14(3):373-82. DOI: 10.1152/jappl.1959.14.3.373. View

19.

Ghaderi Aram M, Zanoli M, Nordstrom H, Toma-Dasu I, Blomgren K, Dobsicek Trefna H . Radiobiological Evaluation of Combined Gamma Knife Radiosurgery and Hyperthermia for Pediatric Neuro-Oncology. Cancers (Basel). 2021; 13(13). PMC: 8268088. DOI: 10.3390/cancers13133277. View

20.

Sapareto S, Dewey W . Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys. 1984; 10(6):787-800. DOI: 10.1016/0360-3016(84)90379-1. View